TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:11
ANAVEX LIFE SCIENCES CORP. ( AVXL ) https://www.anavex.com
12.56USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AVXL
30.83%
SPY
32.66%
-29.16%
AVXL
SPY
108.59%
AVXL
394.49%
SPY
302.52%
AVXL
1470.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1048.36
916.17
6.31
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-24.38
0.00
8.72
-3.83
0.00
-37.42
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.8832
-40.81
-41.32
1.24
Other Earnings and Cash Flow Stats:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Net Income TTM ($MM) is -43.00
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Operating Income TTM ($MM) is -52.88
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Owners' Earnings Annual ($MM) is 0.00
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Current Price to Owners' Earnings ratio is 0.00
ANAVEX LIFE SCIENCES CORP. ( AVXL ) EBITDA TTM ($MM) is -13.33
ANAVEX LIFE SCIENCES CORP. ( AVXL ) EBITDA Margin is 0.00%
Capital Allocation:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has paid 0.00 dividends per share and bought back -3.680453 million shares in the past 12 months
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Interest-bearing Debt ($MM) as of last quarter is 0
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Annual Working Capital Investments ($MM) are -1
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Book Value ($MM) as of last quarter is 120
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has 132 million in cash on hand as of last quarter
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has 15 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has 83 common shares outstanding as of last quarter
ANAVEX LIFE SCIENCES CORP. ( AVXL ) has 0 million USD of preferred stock value
Academic Scores:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Altman Z-Score is 37.33 as of last quarter
ANAVEX LIFE SCIENCES CORP. ( AVXL ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
ANAVEX LIFE SCIENCES CORP. ( AVXL ) largest shareholder is owning shares at 0.00 ($MM) value
Donhauser Peter D.O.(an insider) Bought 2835 shares of ANAVEX LIFE SCIENCES CORP. ( AVXL ) for the amount of $10319.40 on 2024-06-14
3.05% of ANAVEX LIFE SCIENCES CORP. ( AVXL ) is held by insiders, and 32.04% is held by institutions
ANAVEX LIFE SCIENCES CORP. ( AVXL ) went public on 2006-08-02
Other ANAVEX LIFE SCIENCES CORP. ( AVXL ) financial metrics:
FCF:-30.82
Unlevered Free Cash Flow:0.00
EPS:-0.56
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-38.65
Beta:1.24
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ANAVEX LIFE SCIENCES CORP. ( AVXL ) :
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.